Navigation
-
Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall
-
Advaxis Completes $17 Million Financing
-
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers
-
Advaxis's Cancer Immunotherapies Featured on FOX News
-
Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology
-
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer
-
Advaxis to Present at the LD Micro Conference
-
Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program
-
Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer
-
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer
